Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 132 papers

An Assessment of Global Chemistry, Manufacturing and Controls (CMC) Regulatory Requirements in Low and Middle Income Countries

11/2018 - WHO Drugs Journal

Author(s): Rajneesh Taneja, Christine Chacko, Kedar Gumaste, Subina Surendran, Arturo Olguin Pelayo, Adrienne VidalIrizarry, Diana Elkis, Arran Basra, Myrto Lee, Robert Franco

Tags: Advocacy, TB Market, TB-HIV

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMox TB study

10/2018 - BMC Medicine (2018) 16:189

Author(s): Murphy, M.; Wills, G; Murthy, S.; Louw, C.; Bateson, A.; Hunt, R.; McHugh, T.; Nunn, A.; Meredith, S.; Mendel, C.; Spigelman, M.; Crook, A.; Gillespie, S.

Tags: ReMoxTB

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

7/2018 - BMC Infectious Diseases

Author(s): Tweed, Conor D., Crook, Angela M. Amukoye, Evans I. Dawson, Rodney Diacon, Andreas H. Hanekom, Madeline McHugh, Timothy D. Mendel, Carl M. Meredith, Sarah K. Murphy, Michael E. Murthy, Saraswathi E. Nunn, Andrew, Spigelman, M.

Tags: Clinical Trial Results, ReMoxTB

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

12/2017 - BMC Medicine 2017 15:207

Author(s): Patrick P. J. Phillips, Carl M. Mendel, Andrew J. Nunn, Timothy D. McHugh, Angela M. Crook, Robert Hunt, Anna Bateson and Stephen H. Gillespie

Tags: Clinical Trial Results, ReMoxTB

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

12/2017 - BMC Medicine 2017 15:207

Author(s): Patrick P. J. Phillips, Carl M. Mendel, Andrew J. Nunn, Timothy D. McHugh, Angela M. Crook, Robert Hunt, Anna Bateson and Stephen H. Gillespie

Tags: Clinical Trial Results, ReMoxTB

Tuberculosis and antimicrobial resistance - new models of research and development needed

5/2017 - Bulletin of the World Health Organization

Author(s): Brigden G, Castro JL, Ditiu L, Gray G, Hanna D, Low M, Matsoso MP, Perry G, Spigelman M, Swaminathan S, Torreele E, Wong S

Tags: MDR-TB, TB Burden, XDR-TB

The impact of HIV and antiretroviral therapy on TB risk in children: A systematic review and meta-analysis

1/2017 - Thorax Online, 23 Jan. 2017. Web. 31 Jan. 2017.

Author(s): Dodd, P. J., A. J. Prendergast, C. Beecroft, B. Kampmann, and J. A. Seddon. "The Impact of HIV and Antiretroviral Therapy on TB Risk in Children: A Systematic Review and Meta-analysis."

Tags: Childhood TB, Clinical Trial Results, TB-HIV

TB Alliance regimen development for multidrug-resistant tuberculosis

12/2016 - The International Journal of Tuberculosis and Lung Disease

Author(s): Murray, S., Mendel, C., & Spigelman, M.

Tags: Linezolid, MDR-TB, NC-005, Nix-TB, STAND/NC-006

Tuberculosis

10/2016 - Tuberculosis.Nature Reviews Disease Primers. 2016/10/27/online. 16076. Macmillan Publishers Limited. http://dx.doi.org/10.1038/nrdp.2016.76

Author(s): Pai, Madhukar; Behr, Marcel A.; Dowdy, David; Dheda, Keertan; Divangahi, Maziar; Boehme, Catharina C.; Ginsberg, Ann; Swaminathan, Soumya; Spigelman, Melvin; Getahun, Haileyesus; Menzies, Dick; Raviglione, Mario

Tags: Clinical Development, Drug Discovery, MDR-TB, TB-HIV

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fl uoroquinolones: results from a multicountry surveillance project

7/2016 - Zignol, Matteo, Anna Dean, and Natavan Alikhanova. "Population-based Resistance of Mycobacterium Tuberculosis." The Lancet (Published Online July 7, 2016 Http://dx.doi.org/10.1016/S1473-3099(16)30190-6):

Tags: Drug-Sensitivity Testing, MDR-TB, Moxifloxacin, Pyrazinamide, TB Burden

Developing a Framework for Evaluating Ethical Outcomes of Good Participatory Practices in TB Clinical Drug Trials

6/2016 - Journal of Empirical Research on Human Research Ethics 1556264616657452, first published on June 30, 2016 doi:10.1177/1556264616657452

Author(s): Kathleen M. MacQueen, Natalie T. Eley, Mike Frick, Laia Ruiz Mingote, Alicia Chou, Stephanie S. Seidel, Stacey Hannah, and Carol Hamilton

Tags: Advocacy, Clinical Development, Community Engagement, TB-HIV, Trial Design

Global burden of drug-resistant tuberculosis in children: a mathematical modelling study

6/2016 - Peter J Dodd, Charalambos Sismanidis, James A Seddon. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. The Lancet Infectious Diseases , Volume 0 , Issue 0

Tags: Childhood TB, MDR-TB, TB Burden, XDR-TB

Grand Convergence: Aligning Technologies & Realities in Global Health

3/2016 - Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.

Tags: Advocacy, Editorials, Policy, TB Burden

The Zika Loopholes: The FDA has a smart-sounding program to drive research for neglected diseases—with two big flaws

3/2016 - Brock WR, Cohen R, Cone J, McKenna L. The Zika Loopholes: The FDA.... March 25, 2016. http://www.politico.com/agenda/story/2016/03/the-right-way-to-encourage-companies-to-develop-a-treatment-for-zika-000079. Accessed March 25, 2016.

Tags: Editorials

"Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments

3/2016 - Sismanidis C, Glaziou P, Bloss E, et. al. "Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments. 2016 Mar

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB Drug Market, TB Market

Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance

3/2016 - Sismanidis C, Glaziou P, Bloss E, et. al. Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance. 2016 Mar.

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB Drug Market, TB Market

Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence

3/2016 - Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.

Tags: Advocacy, Editorials, Policy, TB Burden

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults

3/2016 - Furin J., Alirol E, Allen E, et. al. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 20161 Mar; 20(3): 290-294.

Tags: Clinical Development, Editorials, MDR-TB, Trial Design, XDR-TB

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

3/2016 - Phillips PPJ, Mendel CM, Burger DA, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine. 2016 Mar.14:19. doi: 10.1186/s12916-016-0565-y

Tags: Biomarkers, Clinical Development, Moxifloxacin, ReMoxTB, Trial Design

The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines

1/2016 - Bekker A, Schaaf HS, Murray S, et. al. The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants... Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600-15. doi: 10.1128/aac.02600-15.

Tags: Childhood TB, Clinical Trial Results, HRZE, Pharmacokinetics, Pyrazinamide

Pages